| 主权项 |
1. A compound of Formula I: or an enantiomer or diastereomer thereof; or a pharmaceutically acceptable salt thereof; wherein ring A is phenyl or a heteroaryl ring selected from pyridyl, thiazolyl, or isoquinolinyl; wherein when ring A is thiazolyl, ring A is optionally substituted with up to 3 substituents selected from R1, R2, R3 or R4, and wherein when ring A is phenyl, pyridyl, or isoquinolinyl, ring A is optionally substituted with up to 4 substituents selected from R1, R2, R3 or R4; R1 is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo or alkyl; R2 is H, alkyl, alkoxy, or halo; Z is NH, N—CH3, N—CH2CH3, N—CH2-cyclopropyl, N—C(═O)CH3, N—CH2CH2OCH3 or O; R3 is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted with up to two substituents selected from halo, alkyl, NO2, or hydroxy-alkoxy; R4 is H or alkyl;
or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl, pyrimidinyl, quinoxalinyl, quinolinyl, or phenyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl pyrimidinyl, quinoxalinyl, quinolinyl, or phenyl is optionally substituted with up to two substituents selected from halo, alkoxy, hydroxymethyl or alkyl; R6A and R6B are independently selected from H, alkyl, hydroxyalkyl, -alkyl-alkoxy, alkyl-alkoxy-alkoxy, or —CO2-alkyl; wherein one or both of R6A and R6B is other than H; and n is 1 or 2. |
